Skip to content

Evaluation of an Osteoporosis Prevention Strategy in Women With Osteoporotic Fracture of the Upper Limb

Secondary Prevention of Osteoporosis in Women Over 50 Years Old After Low Intensity Fracture of the Upper Limb: Evaluation of an Intervention Focused on the Patient.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01780012
Acronym
PREVOST
Enrollment
436
Registered
2013-01-30
Start date
2012-03-31
Completion date
2014-08-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis With Current Fragility Fracture

Keywords

osteoporosis, fragility fracture, secondary prevention

Brief summary

Osteoporosis is a disease characterized by reduced bone mass and increased skeletal fragility, predisposing to an increased fracture risk. The presence of a low trauma fracture is a powerful predictor of future fractures and about 50% of patients with a fragility fracture will suffer a subsequent fracture in the next 10 years (Center Jacqueline R, 2007). Osteoporotic fractures are associated with an increased morbidity and mortality but also high financial costs. However, less than 20% of patients presenting a low trauma fracture receive an appropriate post-fracture osteoporosis management (Little and Eccles, 2010). The hypothesis of a lack of information and an under assessment of consequences by both patients and physicians has been raised to explain this gap between recommended care and usual practices. The aim of the PREVOST program is to assess the efficiency of patient-centered osteoporosis prevention program, after a fragility fracture of the upper limb, to improve post-fracture management of osteoporosis (ie BMD test and / or osteoporosis treatment) in women over 50 years old. This open randomized controlled trial aims to compare the BMD or osteoporosis treatment prescription rate at 6 months after inclusion between two groups: intervention receiving information on fracture and osteoporosis (oral and written), phone call reminders and written information to give to their family physician, and control receiving usual care without information.

Interventions

BEHAVIORALOsteoporosis prevention program

Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Women aged over 50 years * with a fragility fracture of wrist or humerus that occurred in the past 6 months * treated in an emergency department or orthopedic department * who signed the consent form

Exclusion criteria

* no signed consent * previous history of femoral neck fracture * poly-trauma or accident * patients under osteoporosis treatment * patients who performed a BMD test in the past 6 months * patients with severe renal impairment, hyperthyroidism, bone primary or secondary malignancy. * legal disability * difficulty in understanding French * psychiatric disorder

Design outcomes

Primary

MeasureTime frameDescription
Proportion of women in the 2 groups who initiated a management of osteoporosis at 6 months (BMD or osteoporosis treatment prescription).6 months after inclusionAt 6 months, women will be asked whether or not they received a BMD test prescription and/or an osteoporosis treatment prescription by their physician.

Secondary

MeasureTime frameDescription
Proportion of women in the two groups who performed BMD at 6 months6 months after inclusionAt 6 months, women who received a BMD prescription will be asked whether or not they performed a BMD test; if they realized a BMD test, their result will be asked.
Proportion of women in the two groups with an increased perception of fracture risk.6 months after inclusionWomen will answer the same questionnaire at inclusion and at 6 months to assess their fracture risk perception.
Proportion of women in the two groups who changed their behaviour in order to prevent future fractures: regular practice of physical activity, dairy products consumption and calcium and vitamin D supplementation.6 months after inclusion.Women will answer the same questionnaire at inclusion and at 6 months to assess their behaviour towards fracture risk or prevention of osteoporosis: physical activity, dairy products consumption and calcium and vitamin D supplementation
Proportion of women who improved their knowledge about osteoporosis6 months after inclusionWomen will answer the same questionnaire at inclusion and at 6 months to assess their osteoporosis perception and knowledge (risk factors, severity,consequences, treatments)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026